Related Experiment Video
Updated: May 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Multi-Center Real-World Implementation Outcomes of Lenacapavir for HIV Pre-Exposure Prophylaxis
Aniruddha Hazra1,2, Philip A Chan3, Meredith Clement4,5
1Section of Infectious Diseases and Global Health, University of Chicago, Chicago, IL, USA.
Abstract:
Lenacapavir PrEP implementation across 17 U.S. sites (n=501) was characterized by delays in initiation driven by payer processes. Early non-persistence was uncommon (3.6%) but exceeded clinical trial discontinuation rates and was strongly associated with abdominal injections and injection-site reactions requiring clinical contact, underscoring modifiable clinical and structural barriers to early persistence.
More Related Videos
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Antimicrobial Effectiveness
Retroviruses

